Business Context and Reporting Period
Company: Regeneron Pharmaceuticals, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2002
Business Overview: Regeneron is a biopharmaceutical company focused on discovering, developing, and commercializing therapeutic medicines for serious medical conditions. The company has not yet generated sales or profits from the commercialization of its product candidates. Its strategy relies on proprietary technology platforms to develop a pipeline of candidates for obesity, rheumatoid arthritis, cancer, and other disorders, alongside contract manufacturing and research collaborations.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Sep 30, 2002 |
Nine Months Ended Sep 30, 2002 |
Nine Months Ended Sep 30, 2001 |
|---|---|---|---|
| Total Revenues | $6,566 | $17,076 | $17,572 |
| Operating Expenses | $38,742 | $104,395 | $73,662 |
| Net Loss | ($32,816) | ($88,684) | ($47,802) |
| Net Loss Per Share (Basic/Diluted) | ($0.75) | ($2.02) | ($1.15) |
| Cash and Cash Equivalents | $75,574 | See Liquidity Section | |
| Total Liquid Assets (Cash + Securities) | $341,400 | ||
| Long-Term Debt (Convertible Notes) | $200,000 | $200,000 |
Note: All figures in thousands except per share data. Liquid assets include cash, marketable securities, and restricted marketable securities.
Material Changes vs. Prior Period
- Revenue: Total revenue for the nine months ended September 30, 2002, decreased slightly to $17.1 million from $17.6 million in the prior year. This was driven by a decrease in contract research revenue ($8.2M vs $9.4M) due to the completion of studies for Amgen-Regeneron Partners, partially offset by an increase in contract manufacturing revenue ($8.9M vs $8.2M) from a non-recurring $1.0 million payment from Merck.
- Expenses: Total operating expenses increased significantly to $104.4 million for the nine months of 2002, compared to $73.7 million in 2001. Research and development (R&D) expenses rose to $90.5 million from $61.4 million, primarily due to expanded clinical development, specifically the Phase III program for AXOKINE.
- Interest Expense: Interest expense increased by $8.9 million year-over-year to $9.1 million, attributable to interest on $200 million of convertible senior subordinated notes issued in October 2001.
- Cash Flow: Net cash used in operating activities increased to $79.5 million for the nine months of 2002 from $39.7 million in 2001. Net cash used in investing activities was $93.5 million, driven by capital expenditures of $19.2 million and net purchases of marketable securities.
Guidance, Outlook, and Risks
Management Commentary and Outlook: Regeneron anticipates that full-year R&D expenses for 2002 will increase by 30% or more over 2001 levels. The company expects to incur approximately $15 million in capital expenditures for the remainder of 2002. Management believes existing capital resources will enable the company to meet operating needs through at least 2003. Approximately 50-70% of remaining 2002 expenditures are directed toward preclinical and clinical development of product candidates.
Key Risks and Contingencies:
- Clinical Trial Risks: Success is not guaranteed; delays or failures in demonstrating safety or efficacy for candidates like AXOKINE, IL-1 Trap, or VEGF Trap could materially harm the business.
- Regulatory Approval: The company has not received FDA approval for any product. Approval is required before commercial revenues can be realized.
- Immune Response: Recombinant protein therapies may cause immune responses (antibodies) that neutralize effectiveness. Subjects in trials for AXOKINE and IL-1 Trap have developed antibodies.
- Liquidity: The company has no established banking arrangements for short-term financing. Future funding may be required through public/private financing or collaborations, which may not be available on acceptable terms.
- Intellectual Property: Risks include the inability to obtain necessary licenses, challenges to existing patents, or infringement claims by third parties.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $341.4 million in liquid assets against the projected 30%+ increase in R&D spending and $15 million in remaining capital expenditures for 2002.
- AXOKINE Phase III Progress: Monitor the enrollment and interim data of the pivotal 2,000-subject trial for obesity, expected to complete treatment in January 2003.
- Debt Obligations: Review the terms of the $200 million convertible senior subordinated notes (5.5% interest) and the impact of interest expense on net losses.
- Collaboration Revenue Stability: Assess the sustainability of revenue from Procter & Gamble ($2.5M/quarter) and Merck, noting the non-recurring nature of recent Merck payments.
- Antibody Development: Track clinical data regarding the formation of neutralizing antibodies in patients receiving AXOKINE and IL-1 Trap.